2235 related articles for article (PubMed ID: 16890796)
21. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
22. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.
Force T; Kuida K; Namchuk M; Parang K; Kyriakis JM
Circulation; 2004 Mar; 109(10):1196-205. PubMed ID: 15023894
[TBL] [Abstract][Full Text] [Related]
23. Modulation of cell sensitivity to antitumor agents by targeting survival pathways.
Perego P; Cossa G; Zuco V; Zunino F
Biochem Pharmacol; 2010 Nov; 80(10):1459-65. PubMed ID: 20688050
[TBL] [Abstract][Full Text] [Related]
24. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia.
Doepfner KT; Boller D; Arcaro A
Crit Rev Oncol Hematol; 2007 Sep; 63(3):215-30. PubMed ID: 17658267
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy--clinical progress.
Renhowe PA
Curr Opin Drug Discov Devel; 2002 Mar; 5(2):214-24. PubMed ID: 11926128
[TBL] [Abstract][Full Text] [Related]
26. Anti-tumor chemotherapy utilizing peptide-based approaches--apoptotic pathways, kinases, and proteasome as targets.
Mendoza FJ; Espino PS; Cann KL; Bristow N; McCrea K; Los M
Arch Immunol Ther Exp (Warsz); 2005; 53(1):47-60. PubMed ID: 15761376
[TBL] [Abstract][Full Text] [Related]
27. The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies.
Milella M; Kornblau SM; Andreeff M
Rev Clin Exp Hematol; 2003 Jun; 7(2):160-90. PubMed ID: 14763161
[TBL] [Abstract][Full Text] [Related]
28. Aurora kinases: new targets for cancer therapy.
Carvajal RD; Tse A; Schwartz GK
Clin Cancer Res; 2006 Dec; 12(23):6869-75. PubMed ID: 17145803
[TBL] [Abstract][Full Text] [Related]
29. New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation.
Lee AV; Schiff R; Cui X; Sachdev D; Yee D; Gilmore AP; Streuli CH; Oesterreich S; Hadsell DL
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):516S-23S. PubMed ID: 12538509
[TBL] [Abstract][Full Text] [Related]
30. Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun, and ERK activation.
Nickischer D; Laethem C; Trask OJ; Williams RG; Kandasamy R; Johnston PA; Johnston PA
Methods Enzymol; 2006; 414():389-418. PubMed ID: 17110204
[TBL] [Abstract][Full Text] [Related]
31. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
Friday BB; Adjei AA
Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
[TBL] [Abstract][Full Text] [Related]
32. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways.
Guo C; Gasparian AV; Zhuang Z; Bosykh DA; Komar AA; Gudkov AV; Gurova KV
Oncogene; 2009 Feb; 28(8):1151-61. PubMed ID: 19137016
[TBL] [Abstract][Full Text] [Related]
33. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
34. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
35. Tyrosine kinase receptors as attractive targets of cancer therapy.
Bennasroune A; Gardin A; Aunis D; Crémel G; Hubert P
Crit Rev Oncol Hematol; 2004 Apr; 50(1):23-38. PubMed ID: 15094157
[TBL] [Abstract][Full Text] [Related]
36. [The signal transduction pathway of multi-target kinase inhibitors as anticancer agents in clinical use or in phase III].
Wu W; Lu C; Chen SY; Yu NF
Yao Xue Xue Bao; 2009 Mar; 44(3):242-57. PubMed ID: 19449520
[TBL] [Abstract][Full Text] [Related]
37. Targeting PI3K-AKT pathway for cancer therapy.
Lu Y; Wang H; Mills GB
Rev Clin Exp Hematol; 2003 Jun; 7(2):205-28. PubMed ID: 14763163
[TBL] [Abstract][Full Text] [Related]
38. Is there a future for Aurora kinase inhibitors for anticancer therapy?
Carpinelli P; Moll J
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
[TBL] [Abstract][Full Text] [Related]
39. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
[TBL] [Abstract][Full Text] [Related]
40. Targeting silibinin in the antiproliferative pathway.
Li L; Zeng J; Gao Y; He D
Expert Opin Investig Drugs; 2010 Feb; 19(2):243-55. PubMed ID: 20047507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]